Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression

Laboratory Investigation

Volumn 89, Issue 2, 2009, Pages 164-177

  Mii, Akiko ^a   Shimizu, Akira ^a   Masuda, Yukinari ^a   Ishizaki, Masamichi ^a   Kawachi, Hiroshi ^b   Iino, Yasuhiko ^a   Katayama, Yasuo ^a   Fukuda, Yuh ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Acute glomerular injury; Angigotensin II type 2 receptor; Angiotensin II type 1 receptor; ARB; Renoprotection; Thy 1 glomerulonephritis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DESMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEPHRIN; OLMESARTAN; PLATELET DERIVED GROWTH FACTOR B; PODOPLANIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY; CELL ACTIVATION; CELL DESTRUCTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM; EPITHELIUM CELL; GLOMERULOPATHY; GLOMERULUS EPITHELIUM; HISTOPATHOLOGY; KIDNEY FUNCTION; MACROPHAGE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIGENS, THY-1; BIOLOGICAL MARKERS; BLOOD PRESSURE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; IMIDAZOLES; KIDNEY GLOMERULUS; MALE; PLATELET-DERIVED GROWTH FACTOR; PROTEINURIA; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; TETRAZOLES;

EID: 59049083015     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.128     Document Type: Article

References (58)

1. Skeggs LT, Dorer FE, Kahn JR, et al. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 1976;60:737-748.
2. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-1219.
3. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000;35:179-188.
4. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-272.
5. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006;17:2985-2991.
6. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006;70:1914-1919.
7. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 2007;18:2439-2446.
8. Remuzzi A, Gagliardini E, Donadoni C, et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-894.
9. Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-976.
10. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006;1:1054-1065.
11. Shigematsu H. Histological grading and staging of IgA nephropathy. Pathol Int 1997;47:194-202.
12. Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H.S. Lee's glomerular grading system. Nephrol Dial Transplant 2005;20:342-348.
13. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-2163.
14. Szeto CC, Choi PC, To KF, et al. Grading of acute and chronic renal lesions in Henoch-Schonlein purpura. Mod Pathol 2001;14:635-640.
15. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
16. Bagchus WM, Hoedemaeker PJ, Rozing J, et al. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 1986;55:680-687.
17. Ishizaki M, Masuda Y, Fukuda Y, et al. Experimental mesangioproliferative glomerulonephritis in rats induced by intravenous administration of anti-thymocyte serum. Acta Pathol Jpn 1986;36:1191-1203.
18. Shimizu A, Kitamura H, Masuda Y, et al. Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 1995;47:114-121.
19. Shimizu A, Masuda Y, Kitamura H, et al. Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 1998;79:206-214.
20. Shimizu A, Masuda Y, Kitamura H, et al. Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis. Nephron 2000;86:152-160.
21. Han GD, Suzuki K, Koike H, et al. IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol 2006;17:442-453.
22. Morioka Y, Koike H, Ikezumi Y, et al. Podocyte injuries exacerbate mesangial proliferative glomerulonephritis. Kidney Int 2001;60:2192-2204.
23. Hsu SM, Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 1982;30:1079-1082.
24. Shimizu A, Masuda Y, Mori T, et al. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004;15:2655-2665.
25. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92:10663-10667.
26. AbdAlla S, Lother H, Abdel-tawab AM, et al. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001;276:39721-39726.
27. Suzuki K, Han GD, Miyauchi N, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007;170:1841-1853.
28. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
29. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008;86:615-621.
30. Miyata N, Park F, Li XF, et al. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol 1999;277:F437-F446.
31. Ozono R, Wang ZQ, Moore AF, et al. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997;30:1238-1246.
32. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-163.
33. Wagner J, Gehlen F, Ciechanowicz A, et al. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999;10:545-551.
34. Wehbi GJ, Zimpelmann J, Carey RM, et al. Early streptozotocin-diabetes mellitus down regulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001;280:F254-F265.
35. Bonnet F, Candido R, Carey RM, et al. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J Hypertens 2002;20:1615-1624.
36. Benigni A, Tomasoni S, Gagliardini E, et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-948.
37. Amann K, Simonaviciene A, Medwedewa T, et al. Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 2001;12:2572-2584.
38. Manucha W, Oliveros L, Carrizo L, et al. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney Int 2004;65:2091-2107.
39. Nagai Y, Yao L, Kobori H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711.
40. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-296.
41. Zoja C, Abbate M, Corna D, et al. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 1998;31:453-463.
42. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570-1580.
43. Nakamura T, Obata J, Kimura H, et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877-889.
44. Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int 2000;57:1493-1501.
45. Nagamatsu T, Oka T, Nagao T, et al. Effects of KD3-671, an angiotensin II type 1 receptor antagonist, on anti-thy-1 nephritis in rats. Biol Pharm Bull 2003;26:808-812.
46. Mahmood J, Khan F, Okada S, et al. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int 2006;70:1591-1598.
47. Liu N, Shimizu S, Ito-Ihara T, et al. Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system. Nephron Exp Nephrol 2007;105:e65-e74.
48. Yu L, Border WA, Anderson I, et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004;66:1774-1784.
49. Kondo S, Shimizu M, Urushihara M, et al. Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. J Am Soc Nephrol 2006;17:783-794.
50. Okamura A, Rakugi H, Ohishi M, et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999;17:537-545.
51. Ma J, Matsusaka T, Yang H, et al. Local actions of endogenous angiotensin II in injured glomeruli. J Am Soc Nephrol 2004;15:1268-1276.
52. Kakinuma Y, Kawamura T, Bills T, et al. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992;42:46-55.
53. Suganuma E, Zuo Y, Ayabe N, et al. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 2006;17:433-441.
54. Zambidis ET, Park TS, Yu W, et al. Expression of ACE (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008;112:3601-3614.
55. Dezso K, Jelnes P, Laszlo V, et al. Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration. Am J Pathol 2007;171:1529-1537.
56. Tuffin G, Huwyler J, Waelti E, et al. Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat. J Drug Target 2008;16:156-166.
57. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006;17:932-942.
58. Rookmaaker MB, Smits AM, Tolboom H, et al. Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol 2003;163:553-562.